RxDoctor Payments Data

Nasser Sukhon, MD

Internal Medicine · Ann Arbor, MINPI 1497753263

Payments from drug & device makers

$4,698in general payments, 2019–2025

Across 204 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$492
  • Pfizer$480
  • Kowa Pharmaceuticals America, Inc.$460
  • Boehringer Ingelheim$324
  • Exact Sciences$319
  • Biohaven Pharmaceutical Holding Company Ltd.$319
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$4,698100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,698 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$44,054
Medicare patients
87
Services billed
4,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$102,868
EliquisApixaban53$65,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$54,992
TrulicityDulaglutide16$36,585
JardianceEmpagliflozin14$14,574
Atorvastatin Calcium299$4,658
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl16$3,920
Tamsulosin Hcl134$3,226
Metoprolol Succinate122$2,257
Amlodipine Besylate119$1,392
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide64$1,391
Losartan Potassium102$1,340
SynthroidLevothyroxine Sodium12$1,329
Ezetimibe71$1,305
Lisinopril115$1,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$296$102,86866 claims
PfizerEliquis$480$65,38853 claims
GSKTrelegy Ellipta$222$54,99246 claims
Lilly USA, LLCTrulicity$266$36,58516 claims
Boehringer IngelheimJardiance$324$14,57414 claims
AbbVieSynthroid$271$1,32912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →